A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Caba, Buenos Aires 1426, Argentina
Capital Federal, Buenos Aires 1264, Argentina
Capital Federal, Buenos Aires 1280, Argentina
Bogota, Cundinamarca 0, Colombia
Kita-Gun, Kagawa-ken 7610793, Japan
Suita-shi, Osaka 565-0871, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Chuo-ku, Tokyo 1040045, Japan
Minato-ku, Tokyo 1058470, Japan
Badalona-barcelona, 08916, Spain
Pozuelo de Alarcon, Madrid, 28223, Spain
Taoyuan County, 333, Taiwan
Edrine, 22010, Turkey (Türkiye)